Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment

被引:0
|
作者
Li, Shaobo [1 ,2 ]
Zhang, Min [3 ]
Liu, Jin [4 ]
Liu, Shaojun [3 ]
Zhu, Chen [1 ]
Shang, Da [3 ]
Guan, Yi [3 ]
Wang, Qian [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China
[2] Inner Mongolia Med Univ, Peking Univ Canc Hosp, Dept Nucl Med, Affiliated Canc Hosp, Inner Mongolia Campus, Hohhot 010020, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200040, Peoples R China
[4] Naval Med Univ, Changzheng Hosp, Dept Hematol Myeloma & Lymphoma Ctr, Shanghai 200003, Peoples R China
关键词
Multiple myeloma; Myeloma nephropathy; Renal impairment recovery; Risk nomogram; BORTEZOMIB-BASED CHEMOTHERAPY; CAST NEPHROPATHY; STAGING SYSTEM; HIGH-CUTOFF; FAILURE; HEMODIALYSIS; DISEASE; SAFETY; INDEPENDENCE; MULTICENTER;
D O I
10.1016/j.currproblcancer.2023.100962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine risk factors affecting renal recovery in newly diagnosed multiple myeloma (NDMM) patients with renal impairment (RI) and establish a risk nomogram. This multi-center, retrospective cohort study included 187 NDMM patients with RI, 127 of whom were admitted to Huashan Hospital and assigned to the training cohort and 60 were admitted to Changzheng Hospital and assigned to the external validation cohort. The baseline data of the 2 cohorts were compared, and survival and renal recovery rates were analyzed. Independent risk factors affecting renal recovery were determined by binary logistic regression analysis, and a risk nomogram was established and subsequently tested in the external validation cohort. Results: The median overall survival (OS) improved in patients who achieved renal recovery etc within 6 courses of MM directed treatment compared with patients without renal recovery. Median time to renal recovery was 2.65 courses, and the cumulative renal recovery rate during the first 3 courses was 75.05%. Involved serum free light chain (sFLC) ratio of > 120 at diagnosis, time from renal impairment to treatment > 60 days, and a hematologic response without a very good partial remission (VGPR) or better resulted as independent risk factors for renal recovery during the first 3 courses. The established risk nomogram had good discriminative ability and accuracy. Involved sFLC was a key factor affecting renal recovery. Starting treatment as soon as possible after detecting RI and achieving deep hematologic remission during the first 3 courses of treatment helped achieve renal recovery and improve prognosis.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma
    Kobayashi, Hiroki
    Terao, Toshiki
    Tsushima, Takafumi
    Abe, Yoshiaki
    Miura, Daisuke
    Narita, Kentaro
    Kitadate, Akihiro
    Takeuchi, Masami
    Matsue, Kosei
    CANCER MEDICINE, 2020, 9 (12): : 4460 - 4466
  • [22] Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment
    Joao, Cristina
    Freitas, Jose
    Gomes, Fernando
    Geraldes, Catarina
    Coelho, Ines
    Neves, Manuel
    Lucio, Paulo
    Esteves, Susana
    Esteves, Graca V.
    ANNALS OF HEMATOLOGY, 2016, 95 (06) : 931 - 936
  • [23] Superior myeloma response with bortezomib-based regimen in multiple myeloma patients with renal impairment
    Bao, Li
    Lu, Jin
    Wang, Shihua
    Huang, Xiaojun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (03): : 6200 - 6209
  • [24] Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit
    Dimopoulos, M. A.
    Roussou, M.
    Gavriatopoulou, M.
    Fotiou, D.
    Ziogas, D. C.
    Migkou, M.
    Panagiotidis, I.
    Eleutherakis-Papaiakovou, E.
    Kanellias, N.
    Psimenou, E.
    Marinaki, S.
    Bacharaki, D.
    Mparmparoussi, D.
    Matsouka, C.
    Giannouli, S.
    Terpos, E.
    Kastritis, E.
    BLOOD CANCER JOURNAL, 2017, 7 : e571 - e571
  • [25] Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma
    Mizuno, Shinichi
    Kitayama, Chigusa
    Mashiko, Shigeto
    Sanada, Satoru
    CEN CASE REPORTS, 2022, 11 (02) : 265 - 268
  • [26] Kidney function in newly diagnosed myeloma patients: factors associated with kidney impairment and recovery
    Cesar, Bruno Nogueira
    Braga, Walter Moises Tobias
    Hamerschlak, Nelson
    Durao Junior, Marcelino de Souza
    BMC NEPHROLOGY, 2024, 25 (01)
  • [27] CLINICAL IMPORTANCE OF RENAL RECOVER ON OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE AND DIALYSIS-DEPENDENT KIDNEY FAILURE
    Semochkin, S., V
    Zhelnova, E., I
    Misyurina, E. N.
    Maryin, D. S.
    Ushakova, A., I
    Karimova, E. A.
    Baryakh, E. A.
    Tolstykh, T. N.
    Mavrina, E. S.
    Yurova, E., V
    Cherkasova, A., V
    Grishina, E. Yu
    Gagloeva, D. E.
    Yatskov, K., V
    Kotenko, O. N.
    Lysenko, M. A.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2019, 64 (03): : 283 - 296
  • [28] Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma
    Gaffney, Kelly J.
    Bakos, Jonathan K.
    Velayati, Arash
    Davis, James A.
    Thurlapati, Aswani
    Weeda, Erin
    Maldonado, Andy
    Granger, Katelynn
    Butcher, Coleen
    Herrington, Taylor
    Smith, Deidra
    Green, Kimberly
    Hess, Brian T.
    Hashmi, Hamza
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (01) : 72 - 80
  • [29] VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
    Dimopoulos, Meletios A.
    Richardson, Paul G.
    Schlag, Rudolf
    Khuageva, Nuriet K.
    Shpilberg, Ofer
    Kastritis, Efstathios
    Kropff, Martin
    Petrucci, Maria T.
    Delforge, Michel
    Alexeeva, Julia
    Schots, Rik
    Masszi, Tamas
    Mateos, Maria-Victoria
    Deraedt, William
    Liu, Kevin
    Cakana, Andrew
    van de Velde, Helgi
    Miguel, Jesus F. San
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) : 6086 - 6093
  • [30] Factors Associated with Recovery of Renal Function in Patients with Multiple Myeloma Who Were Treated with Hemodialysis
    Katagiri, Daisuke
    Hagiwara, Shotaro
    Minami, Eri
    Katsuma, Ai
    Masumoto, Shoichi
    Hoshino, Taro
    Inoue, Tsuyoshi
    Shibata, Maki
    Tada, Manami
    Nakamura, Taichi
    Shimbo, Takuro
    Hinoshita, Fumihiko
    NEPHRON CLINICAL PRACTICE, 2011, 117 (01): : C28 - C32